文献类型：期刊文献

英文题名：Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1

作者：Yu, Cheng[1,2];Su, Yuanhui[1];Miao, Xin[3,4];Chai, Changpeng[1,5];Tang, Huan[1];Li, Lu[5];Yi, Jianfeng[6,7];Ye, Zhenzhen[1,7];Zhang, Hui[1,8];Hu, Zhao[4,9];Chen, Luyang[4,9];Li, Ning[4,9];Xu, Hao[4,9];Zhou, Wence[1,8]

第一作者：Yu, Cheng

通信作者：Zhou, WC[1];Li, N[2];Xu, H[2];Zhou, WC[3];Li, N[4];Xu, H[4]

机构：[1]Lanzhou Univ, Clin Med Sch 2, Lanzhou 730000, Peoples R China;[2]Lanzhou Univ, Hosp 2, Dept Anesthesiol, Lanzhou 730000, Peoples R China;[3]Zhejiang Chinese Med Univ, Affiliated Hosp 1, Zhejiang Prov Hosp Chinese Med, Hangzhou 310006, Peoples R China;[4]Zhejiang Chinese Med Univ, Sch Clin Med 1, Hangzhou 310006, Peoples R China;[5]Lanzhou Univ, Hosp 1, Dept Gen Surg 4, Lanzhou 730000, Peoples R China;[6]Lanzhou Univ, Clin Med Sch 1, Lanzhou 730000, Peoples R China;[7]Gansu Univ Chinese Med, Sch Clin Med 1, Lanzhou 730000, Peoples R China;[8]Lanzhou Univ, Hosp 2, Dept Gen Surg, 82 Cuiyingmen, Lanzhou 730000, Peoples R China;[9]Zhejiang Chinese Med Univ, Zhejiang Prov Hosp Chinese Med, Affiliated Hosp 1, Dept Hepatobiliary Surg, Hangzhou 310006, Peoples R China

第一机构：Lanzhou Univ, Clin Med Sch 2, Lanzhou 730000, Peoples R China

通信机构：[1]corresponding author), Lanzhou Univ, Clin Med Sch 2, Lanzhou 730000, Peoples R China;[2]corresponding author), Zhejiang Chinese Med Univ, Sch Clin Med 1, Hangzhou 310006, Peoples R China;[3]corresponding author), Lanzhou Univ, Hosp 2, Dept Gen Surg, 82 Cuiyingmen, Lanzhou 730000, Peoples R China;[4]corresponding author), Zhejiang Chinese Med Univ, Zhejiang Prov Hosp Chinese Med, Affiliated Hosp 1, Dept Hepatobiliary Surg, Hangzhou 310006, Peoples R China.

年份：2024

卷号：24

期号：1

外文期刊名：BMC CANCER

收录：;Scopus(收录号：2-s2.0-85197520448);WOS:【SCI-EXPANDED(收录号:WOS:001262296100002)】；

基金：This work was supported by grants from National Natural Science Foundation of China (Grant 82360510), Medical Innovation and Development Project of Lanzhou University (Grant lzuyxcx-2022-177), Major Science and Technology Projects of Gansu Province (Grant 22ZD6FA021-4), Science and Innovation Foundation of Gansu University of Chinese Medicine (Grants 2020KCZD-6 and 2020KCYB-10), Open Project of Gansu Provincial Key Laboratory for Mining and Innovation Transformation of Traditional Chinese Medicine (Grant ZYZX-2020-08), Lanzhou Science and Technology Plan Project (Grant 2020-ZD-60).

语种：英文

外文关键词：Pancreatic cancer; Tumor cell line; Chemotherapy; Intrinsic multidrug resistance; Transplanted tumor

摘要：Drug resistance remains a significant challenge in the treatment of pancreatic cancer. The development of drug-resistant cell lines is crucial to understanding the underlying mechanisms of resistance and developing novel drugs to improve clinical outcomes. Here, a novel pancreatic cancer cell line, PDAC-X1, derived from Chinese patients has been established. PDAC-X1 was characterized by the immune phenotype, biology, genetics, molecular characteristics, and tumorigenicity. In vitro analysis revealed that PDAC-X1 cells exhibited epithelial morphology and cell markers (CK7 and CK19), expressed cancer-associated markers (E-cadherin, Vimentin, Ki-67, CEA, CA19-9), and produced pancreatic cancer-like organs in suspension culture. In vivo analysis showed that PDAC-X1 cells maintained tumorigenicity with a 100% tumor formation rate. This cell line exhibited a complex karyotype, dominated by subtriploid karyotypes. In addition, PDAC-X1 cells exhibited intrinsic multidrug resistance to multiple drugs, including gemcitabine, paclitaxel, 5-fluorouracil, and oxaliplatin. In conclusion, the PDAC-X1 cell line has been established and characterized, representing a useful and valuable preclinical model to study the underlying mechanisms of drug resistance and develop novel drug therapeutics to improve patient outcomes.